Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results – Continued execution of global endocrinology rare disease programs as planned regulatory filings for TransCon™ hGH in 2020 advance on track – – Expanded PaTH Forward Trial expedites enrollment of...

Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency - TransCon hGH demonstrated comparable safety and tolerability to a daily hGH - - Potential once-weekly treatment option to overcome long-standing challenges with administration of daily hGH - -...